dc.contributor.author | Szejniuk, Weronika Maria | |
dc.contributor.author | Cekala, M. | |
dc.contributor.author | Bøgsted, Martin | |
dc.contributor.author | Meristoudis, Christos | |
dc.contributor.author | McCulloch, Tine | |
dc.contributor.author | Falkmer, Ursula | |
dc.contributor.author | Røe, Oluf Dimitri | |
dc.date.accessioned | 2023-02-06T10:28:27Z | |
dc.date.available | 2023-02-06T10:28:27Z | |
dc.date.created | 2021-04-29T13:15:38Z | |
dc.date.issued | 2021 | |
dc.identifier.citation | Cancer Treatment and Research Communications. 2021, 27:100318 1-6. | en_US |
dc.identifier.issn | 2468-2942 | |
dc.identifier.uri | https://hdl.handle.net/11250/3048516 | |
dc.description.abstract | Background
The study investigated the association of the relative dose-intensity (RDI) of cisplatin and timing of adjuvant platinum-based chemotherapy (APC) with survival for stage I-III non-small cell lung cancer (NSCLC) patients.
Material and Methods
Real-life data of patients treated with APC (four cycles of cisplatin and vinorelbine) between 2007 and 2014 was included to analyse the association between disease-free survival (DFS) and overall survival (OS) with RDI (ratio of received to planned dose-intensity). High RDI was defined as cisplatin RDI of > 75% and low RDI ≤ 75%.
Results
Out of 198 patients, 166 were eligible. Low RDI was administered to 72 (43%) patients. In multivariate analysis, those patients had a significantly higher risk of recurrence (HR: 1.87, 95%CI 1.13–3.09, p = 0.01) and death (HR: 1.91, 95%CI 1.32–3.23, p = 0.01) versus patients in the high RDI group. The risk of death was significantly higher in patients with PS 1 treated with low versus high RDI (HR: 2.72, 95%CI: 1.22–6.09, p = 0.014). The risk of recurrence was higher for patients with squamous cell carcinoma of low versus high RDI (HR: 3.82, 95%CI: 1.01–14.4, p = 0.048). No impact of delayed APC beyond six weeks from surgery on neither DFS (HR: 0.78, 95%CI: 0.46–1.33, p = 0.36) nor OS (HR 0.67, 95%CI: 0.40–1.15, p = 0.15) was observed.
Conclusion
Low cisplatin RDI ≤ 75% of APC, but not extended time from surgery to APC onset > six weeks, was associated with significantly shorter survival in NSCLC patients. | en_US |
dc.language.iso | eng | en_US |
dc.publisher | Elsevier Science | en_US |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 Internasjonal | * |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/deed.no | * |
dc.title | Adjuvant platinum-based chemotherapy in non-small cell lung cancer: The role of relative dose-intensity and treatment delay | en_US |
dc.title.alternative | Adjuvant platinum-based chemotherapy in non-small cell lung cancer: The role of relative dose-intensity and treatment delay | en_US |
dc.type | Peer reviewed | en_US |
dc.type | Journal article | en_US |
dc.description.version | publishedVersion | en_US |
dc.source.pagenumber | 1-6 | en_US |
dc.source.volume | 27 | en_US |
dc.source.journal | Cancer Treatment and Research Communications | en_US |
dc.identifier.doi | 10.1016/j.ctarc.2021.100318 | |
dc.identifier.cristin | 1907220 | |
dc.source.articlenumber | 100318 | en_US |
cristin.ispublished | true | |
cristin.fulltext | original | |
cristin.qualitycode | 1 | |